Incobotulinumtoxin A for Sialorrhea in Neurological Disorders: A Real-Life Experience

被引：13

作者：

Martinez-Poles, Javier ^{[1
]}

Nedkova-Hristova, Velina ^{[1
]}

Bernardo Escribano-Paredes, Jose ^{[1
]}

Garcia-Madrona, Sebastian ^{[1
]}

Natera-Villalba, Elena ^{[1
]}

Estevez-Fraga, Carlos ^{[1
,2
]}

Lopez-Sendon Moreno, Jose Luis ^{[1
]}

Aviles-Olmos, Iciar ^{[1
]}

Sanchez Diaz, Gema ^{[1
]}

Martinez Castrillo, Juan Carlos ^{[1
]}

Alonso-Canovas, Araceli ^{[1
]}

机构：

[1] Hosp Univ Ramon y Cajal, Dept Neurol, Madrid 28034, Spain

[2] UCL Inst Neurol, Dept Neurodegenerat Dis, London WC1N 3RX, England

来源：

TOXINS | 2018年 / 10卷 / 06期

关键词：

sialorrhea; neurological disorders; Parkinson's disease; botulinum toxin type A; incobotulinumtoxin A; TOXIN TYPE-A; RANDOMIZED CONTROLLED-TRIAL; PARKINSONS-DISEASE; DOUBLE-BLIND; COMPLEXING PROTEINS; BOTULINUM TOXINS; EFFICACY; SAFETY; METAANALYSIS; INJECTION;

D O I：

10.3390/toxins10060217

中图分类号：

TS2 [食品工业];

学科分类号：

0832 ;

摘要：

Botulinum toxin type A is one of the most useful treatments of sialorrhea in neurological disorders. Evidence for the use of incobotulinumtoxin A (inco-A) in the treatment of sialorrhea is limited. Thirty-six patients with sialorrhea were treated with infiltrations of inco-A into both parotid glands. The severity of sialorrhea was evaluated by the Drooling Severity Scale (DSS), and the Drooling Frequency Scale (DFS). Patients' perceptions of clinical benefit were recorded via the Patient Global Impression of Improvement (PGI-I) scale. Following treatment, there was a significant difference in both the DFS and the DSS (p < 0.001). Clinical benefits on the basis of the PGI-I were present in up to 90% of patients.

引用

页数：8

共 50 条

[31] Queue scheduling at the JCMT: the real-life experience
Tilanus, RPJ
[J]. ASTRONOMICAL DATA ANALYSIS SOFTWARE AND SYSTEMS IX, 2000, 216 : 101 - 110
[32] REAL-LIFE EXPERIENCE WITH IBRUTINIB IN A REGIONAL HOSPITAL
Bobes, Fernandez A. M.
Taboada, Alameda F.
Ramirez, Garcia I.
Fernandez, Bobela R.
Chamorro, Fernandez C.
[J]. HAEMATOLOGICA, 2020, 105 : 389 - 389
[33] Mepolizumab in rare eosinophilic disorders: A real-life study
Demir, S.
Korkmaz, P.
Karabacak, D. Eyice
Unal, D.
Ince, B.
Erdem, S.
Dincer, Z. Toker
Sumer, C.
Hatemi, G.
Seyahi, E.
Bingol, Z.
Inanc, M.
Besisik, S. Kalayoglu
Akkor, A.
[J]. ALLERGY, 2023, 78
[34] Subcutaneous abatacept in rheumatoid arthritis: A real-life experience
Camilo Sarmiento-Monroy, Juan
Parada-Arias, Luisa
Rodriguez-Lopez, Milena
Rodriguez-Jimenez, Monica
Molano-Gonzalez, Nicolas
Rojas-Villarraga, Adriana
Dario Mantilla, Ruben
[J]. JOURNAL OF TRANSLATIONAL AUTOIMMUNITY, 2019, 2
[35] Sorafenib for Advanced Hepatocellular Carcinoma: A Real-Life Experience
Longo, Larisse
Rodrigues de Freitas, Laura Bainy
Santos, Deivid
Grivicich, Ivana
Alvares-da-Silva, Mario Reis
[J]. DIGESTIVE DISEASES, 2018, 36 (05) : 377 - 384
[36] Real-life experience of familial fibrosis in a Belgian university
Petit, Anne-sophie
Dahlqvist, Caroline
De Leener, Anne
Kannengiesser, Caroline
Borie, Raphael
Froidure, Antoine
[J]. EUROPEAN RESPIRATORY JOURNAL, 2019, 54
[37] Real-life experience of eribulin in patients with advanced liposarcoma
Rodriguez Ramallo, H.
Jimenez Galan, R.
Baez Gutierrez, N.
Flores Moreno, S.
Abdelkader Martin, L.
Vega Coca, M. D.
Seisdedos Elcuaz, R.
[J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 75 : S16 - S16
[38] Prosigna test in breast cancer: real-life experience
Hequet, D.
Harrissart, G.
Krief, D.
Maumy, L.
Lerebours, F.
Menet, E.
Callens, C.
Rouzier, R.
[J]. BREAST CANCER RESEARCH AND TREATMENT, 2021, 188 (01) : 141 - 147
[39] Indwelling pleural catheters: an overview and real-life experience
Messeder, S. J.
Thomson, M. C.
Hu, M. K.
Chetty, M.
Currie, G. P.
[J]. QJM-AN INTERNATIONAL JOURNAL OF MEDICINE, 2019, 112 (08) : 599 - 604
[40] Epidemiology and real-life experience in progressive pulmonary fibrosis
Valenzuela, Claudia
Cottin, Vincent
[J]. CURRENT OPINION IN PULMONARY MEDICINE, 2022, 28 (05) : 407 - 413

← 1 2 3 4 5 →